Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Sep 26, 2022
Idiopathic pulmonary fibrosis (IPF) is a rare, sporadic, and fatal interstitial lung disease. As the morbidity and mortality rates associated with IPF remain high, prompt idiopathic pulmonary fibrosis treatment is critical to safeguard individuals’ lung function, reduce the risk of acute exacerbations, and improve ...
Read More...
Jul 26, 2019
According to NIH, Idiopathic Pulmonary Fibrosis prevalent cases are estimated to be 13 to 20 per 100,000 people worldwide, making it’s a rare but severe lung disease.Idiopathic Pulmonary Fibrosis (IPF) is progressive and chronic scarring of lung tissues hampering the transport of the oxygen into the bloodstream. T...
Read More...
Jul 12, 2019
Sometimes, something gets missed from our eyes; often, our ignorance delays the diagnosis of something fatal. Idiopathic Pulmonary fibrosis is a chronic, rare, progressive fibrosing interstitial pneumonia. It is a harsh condition that scars the lung tissues for a lifetime and hampers the normal functioning of th...
Read More...
Aug 20, 2018
Idiopathic Pulmonary Fibrosis (IPF) is a debilitating, chronic, fatal disease with an excess fibrous tissue called as fibrosis in the lungs. The idiopathic (unknown cause) character of the disease make it difficult to predict and treat in the initial stages. The irreversible damaging of lungs supporting frame work, ...
Read More...
Nov 22, 2016
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease of unknown etiology, closely associated with interstitial lung disease that shows similar symptoms but with different mode of action. The disease is known so because it primarily involves the interstitium, where scars develop and progresses towards the ce...
Read More...
Mar 18, 2016
DelveInsight is a leading Business Consultant and Market Research Firm which has become the knowledge partner for biotechnology and pharmaceutical companies by providing competitive intelligence information which aids them to strategize and discover the target areas & potential customers for their products. Del...
Read More...
Apr 24, 2023
Bronchiectasis is a chronic respiratory condition where the bronchial tubes in the lungs become damaged, inflamed, and widened, leading to a buildup of mucus that makes breathing difficult. The condition can develop for various reasons, including infections, genetic disorders, autoimmune conditions, and other facto...
Read More...
Nov 28, 2022
Chronic pulmonary hypertension (CPH) encompasses a heterogeneous group of disorders with the common feature of elevated pulmonary vascular resistance, accounting for approximately 42 million cases in 7MM in 2021. As per DelveInsight’s analysis, the 7MM prevalence is expected to increase at a considerable CAGR of 0....
Read More...
Sep 30, 2024
After years of little progress in the field of schizophrenia drug treatment, Bristol Myers Squibb’s $14 billion acquisition of Karuna Therapeutics has paid off with the approval of a groundbreaking new drug. BMS’s novel medication, KarXT—now named COBENFY—received significant FDA approval on 26 September 2024 for t...
Read More...
Aug 20, 2024
Duchenne muscular dystrophy (DMD) is a rare genetic disorder usually diagnosed in young boys, gradually weakening muscles across the body until the heart or lungs fail. Symptoms often show up by the age of 5; as the disease progresses, patients tend to lose the ability to walk around the age of 12. As per a recent ...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper